Mount Sinai Researchers Identify Subtle Changes that May Occur in Neural Circuits Due to Cocaine Addiction
Research May Offer a Unique Pathway for Targeting New Therapeutics for Addiction Treatment
A research team from the Friedman Brain Institute of the Icahn School of Medicine at Mount Sinai has published evidence that shows that subtle changes of inhibitory signaling in the reward pathway can change how animals respond to drugs such as cocaine. This is the first study to demonstrate the critical links between the levels of the trafficking protein, the potassium channels’ effect on neuronal activity and a mouse’s response to cocaine. Results from the study are published in the peer-reviewed journal Neuron on May 7, 2014.
The authors investigated the role of sorting nexin 27 (SNX27), a PDZ-containing protein known to bind GIRK2c/GIRK3 channels, in regulating GIRK currents in dopamine (DA) neurons on the ventral tegmental area (VTA) in mice.
“Our results identified a pathway for regulating the excitability of the VTA DA neurons, highlighting SNX27 as a promising target for treating addiction,” said Paul A. Slesinger, PhD, Professor, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
“Future research will focus on the role that potassium channels and trafficking proteins have in models of addiction,” said Dr. Slesinger.
Dr. Slesinger was the lead author of the study and joined by Michaelanne B. Munoz from the Graduate Program in Biology, University of California, San Diego and the Peptide Biology Laboratories, The Salk Institute for Biological Studies, La Jolla, California.
The research was supported by grants from the National Institute on Drug Abuse, the Salk Institute Chapman Foundation, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.